Pulsed low-dose radiation vs standard chemoradiation for esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial compares a new way of giving radiation (in short, pulsed low-dose bursts) to the standard method, both combined with chemotherapy, for people with esophageal cancer. It aims to see if the pulsed approach is safer and equally effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have stage II to IVb esophageal cancer (if stage IVb, the cancer has spread to only a few spots, and your doctor thinks you can get full-dose chemoradiation).
- You are currently getting or have already received chemotherapy before starting chemoradiation.
- You are well enough to be up and about at least half the day (ECOG performance status 0-2).
- Your blood counts and kidney and liver function are within safe limits as per recent tests.
- If you are able to become pregnant, you agree to use effective birth control during treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether a combination of chemotherapy and radiation can help people with advanced esophageal cancer who cannot have curative treatment. It focuses on people who are having swallowing trouble and may be able to start treatment soon.
This trial tests whether adding radiation to a combination of chemotherapy and immunotherapy can help people with stage IV esophageal cancer that has spread. It is for those who haven't had any prior treatment for their cancer.
This study tests a new pre-surgery treatment plan that combines chemotherapy with focused, shorter-course radiation for esophagus or stomach-where-it-meets-the-esophagus (GEJ) adenocarcinoma. The goal is to shrink the tumor before surgery and improve treatment outcomes.
This trial compares two standard treatments for esophageal cancer that has responded to initial chemo-immunotherapy: surgery to remove the tumor or radiation combined with chemotherapy. The goal is to see which approach offers better outcomes and quality of life.
This trial tests a new drug that helps the immune system fight cancer, combined with a special type of radiation therapy, for people with esophageal, lung, or cervical cancer that has progressed after initial treatment.
This Phase 3 trial studies giving combined chemotherapy and radiation to treat esophageal cancer that has returned after earlier surgery and/or prior treatments. It may help control the cancer in the area where it comes back, especially when the surgical margins were not fully clear or the cancer is outside the original radiation field.
Hear when a new Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.